A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

← catalyst calendar

NCT07766369 · readout in 85 d

Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

93estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-08-12

estimated

When the study began enrolling

Primary completion

2026-11-12

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-11-12

estimated

The whole study's end, after follow-up

First posted

2026-08-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Volunteers

Intervention

Drug: E2086

Primary outcomes

what the primary-completion date above is the date OF

Part A, area under concentration versus time curve from zero time (predose) to time of last quantifiable concentration AUC(0-t) of E2086 and its Metabolite M1

measured Day 1 to Day 4; Day 7 to Day 13

Part A, area under concentration versus time curve from zero time (predose) to infinite time AUC(0-inf) of E2086 and its Metabolite M1

measured Day 1 to Day 4; Day 7 to Day 13

Part A, maximum observed concentration (Cmax) of E2086 and its Metabolite M1

measured Day 1; Day 7

Part B, AUC(0-t) of midazolam (MDZ)

measured Day 1 to Day 4; Day 15 to Day 18

Part B, AUC(0-t) of dextromethorphan (DEX)

measured Day 1 to Day 4; Day 15 to Day 18

Part B, AUC(0-t) of bupropion (BUP)

measured Day 4 to Day 8; Day 18 to Day 22

Part B, AUC(0-t) of hydroxybupropion

measured Day 4 to Day 8; Day 18 to Day 22

Part B, AUC(0-inf) of MDZ

measured Day 1 to Day 4; Day 15 to Day 18

Part B, AUC(0-inf) of DEX

measured Day 1 to Day 4; Day 15 to Day 18

Part B, AUC(0-inf) of BUP

measured Day 4 to Day 8; Day 18 to Day 22

Part B, AUC(0-inf) of hydroxybupropion

measured Day 4 to Day 8; Day 18 to Day 22

Part B, Cmax of MDZ

measured Day 1 and Day 15

Part B, Cmax of DEX

measured Day 1 and Day 15

Part B, Cmax of BUP

measured Day 4 and Day 18

Part B, Cmax of hydroxybupropion

measured Day 4 and Day 18

Part C, AUC(0-t) of ethinyl estradiol (EE)

measured Day 1 to Day 5; Day 12 to Day 16

Part C, AUC(0-t) of norethindrone (NET)

measured Day 1 to Day 5; Day 12 to Day 16

Part C, AUC(0-inf) of EE

measured Day 1 to Day 5; Day 12 to Day 16

Part C, AUC(0-inf) of NET

measured Day 1 to Day 5; Day 12 to Day 16

Part C, Cmax of EE

measured Day 1; Day 12

Part C, Cmax of NET

measured Day 1 and Day 12

Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed